Needham analyst Gil Blum has maintained their bullish stance on AUTL stock, giving a Buy rating yesterday.
Gil Blum has given his Buy rating due to a combination of factors that highlight the potential of Autolus Therapeutics. The company recently hosted an R&D Day where they shared promising initial clinical results for their product, obe-cel, in treating severe SLE patients. These results showed early signs of efficacy, such as improvements in SLEDAI-2K scores and CRR, without any high-grade CRS or ICANS, and manageable hypertension, indicating a favorable safety profile.
Furthermore, Autolus is planning a pivotal study in 4L LN, aiming to start by the end of 2025, with results expected in 2028/2029. This strategic move is intended to position them ahead of competitors like Novartis. Additionally, the company is initiating a Phase I study in PMS, which has a substantial patient population in the US. With these developments, Needham & Company maintains a Buy rating and a price target of $10, reflecting confidence in Autolus’s growth prospects.